Editas Medicine, Inc. develops genome editing medicines using CRISPR systems for serious diseases. Company news centers on its in vivo pipeline, including EDIT-401, an LDLR-targeted development candidate designed to treat hyperlipidemia by increasing LDLR protein expression and reducing LDL cholesterol.
Recurring updates include quarterly financial results, business highlights, scientific conference presentations, preclinical data for EDIT-401, intellectual property developments involving CRISPR/Cas9 patent interference, and investor conference participation. The company also reports on pipeline prioritization and its licensed Cas12a and Cas9 patent estates for human medicines.
Editas Medicine (Nasdaq: EDIT) announced the submission of an IND application to the FDA for a Phase 1/2 trial of EDIT-301, a CRISPR-based treatment for sickle cell disease. This marks a significant milestone in their development of ex vivo cell therapies. EDIT-301 aims to increase fetal hemoglobin levels to offer a durable treatment solution. The company has appointed a lead principal investigator and engaged a CRO, with clinical trial materials already being manufactured. This submission highlights Editas' commitment to providing transformative therapies for those affected by sickle cell disease.
Editas Medicine announced promising preclinical data for EDIT-301, an innovative autologous cell therapy targeting sickle cell disease and beta-thalassemia. Utilizing CRISPR/Cas12a technology, the therapy demonstrated high gene editing efficiency and significant fetal hemoglobin induction in clinical studies. The company successfully developed a scalable manufacturing process, showing consistent, robust results in animal models. Editas plans to file an IND for EDIT-301 by the end of 2020, aiming to enter a Phase 1/2 clinical trial, potentially offering a transformative solution for patients.
Editas Medicine (Nasdaq: EDIT) has granted inducement awards to Lisa Michaels, M.D., the newly appointed Executive Vice President and Chief Medical Officer. The Board approved a stock option grant for up to 120,000 shares at $30.41 per share, which vests over four years. Additionally, Dr. Michaels received a restricted stock unit award for 20,000 shares, vesting at 25% annually over four years. These awards comply with Nasdaq Listing Rule 5635(c)(4) and are contingent on her continued employment with Editas Medicine.
Editas Medicine, a prominent genome editing company, announced its participation in the Barclays Gene Editing & Gene Therapy Summit on November 16, 2020, at 10:15 AM ET. The presentation will be webcast live on their website, with archived recordings available for 30 days post-event.
Editas focuses on utilizing CRISPR technologies to develop precise genomic medicines aimed at treating serious diseases globally.
Editas Medicine has appointed Lisa A. Michaels, M.D. as its new Executive Vice President and Chief Medical Officer. Dr. Michaels brings over 25 years of experience in clinical research and drug development from her previous role at Bayer Pharmaceuticals. She will oversee clinical research and drug development for Editas' pipeline, notably focusing on EDIT-301 for sickle cell disease. The company recently reacquired rights to its ocular pipeline, enhancing its position in the genome editing landscape.
Editas Medicine announced key developments in its third quarter 2020 financial results. The company has completed dosing for the adult low-dose cohort in the EDIT-101 BRILLIANCE trial and regained full control of its ocular programs through a new agreement with AbbVie. Cash and marketable securities stood at $541 million as of September 30, 2020. EDIT-301 for sickle cell disease is on track for an IND filing by year-end, while EDIT-201's preclinical data will be shared at upcoming conferences. The company reported a net income of $7.8 million in Q3 compared to a net loss of $32.9 million last year.
Editas Medicine, a leading genome editing company, announced a conference call and webcast on November 5, 2020, at 5:00 PM ET to discuss its third-quarter results and corporate updates. Investors can access the call by dialing (844) 348-3801 domestically or (213) 358-0955 internationally. The conference ID is 9992536. A live webcast will be available on the Editas Medicine website.
Editas focuses on developing transformative genomic medicines using CRISPR technology.
On October 1, 2020, Editas Medicine (Nasdaq: EDIT) announced its participation in the Chardan Virtual 4th Annual Genetic Medicines Conference, scheduled for October 5, 2020, at 10:30 a.m. ET. The event will feature a fireside chat and will be webcast live on the company's website, with archived recordings available for 30 days post-event. Editas Medicine focuses on developing transformative genomic medicines using CRISPR technology to treat serious diseases. For more updates, visit www.editasmedicine.com.
Editas Medicine, Inc. (Nasdaq: EDIT) announced that the U.S. Patent and Trademark Office has granted Broad Institute’s motion for priority in a patent interference case. This decision denies priority to CVC, meaning Broad is now the 'Senior Party.' Editas remains confident in its exclusive licenses for foundational CRISPR/Cas9 patents. Broad’s patents are valid in multiple jurisdictions, including the U.S., and Editas aims to leverage these innovations in developing treatments for serious diseases.
Editas Medicine, a leading genome editing company, will participate in several upcoming investor conferences. Key events include Citi’s 15th Annual BioPharma Virtual Conference on September 9, 2020, at 3:20 p.m. ET, a fireside chat at the Wells Fargo 2020 Virtual Healthcare Conference on September 10, 2020, at 10:40 a.m. ET, and another fireside chat at the Morgan Stanley 18th Annual Global Healthcare Conference on September 15, 2020, at 10:15 a.m. ET. These events will be webcast live on the company’s website, with recordings available for 30 days afterwards.